SCHEMBL5714858

SCHEMBL5714858

O=C(Oc1ccc2cccnc2c1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.59
LMNA P02545 3/20 0.59
MEN1 O00255 1/20 0.59
ALDH1A1 P00352 1/20 0.59
KMT2A Q03164 1/20 0.59
SMN1; SMN2 Q16637 5/20 0.56
HPGD P15428 1/20 0.56
TRPV1 Q8NER1 3/20 0.55
L3MBTL1 Q9Y468 1/20 0.54
TRPA1 O75762 2/20 0.54
KDM4E B2RXH2 2/20 0.52
SCN9A Q15858 4/20 0.52
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MAPT P10636 1/20 0.49
IDE P14735 1/20 0.49
LIPE Q05469 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715175 0.87 CHRM1 (0.49) HTTLMNAMEN1ALDH1A1KMT2A
SCHEMBL5714464 0.85 PANK3 (0.46) MEN1KMT2ATRPV1TRPA1KDM4E
SCHEMBL5714539 0.85 TRPA1 (0.53) LMNAMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL5714980 0.84 KMT2A (0.47) HTTLMNAMEN1ALDH1A1KMT2A
SCHEMBL5714487 0.84 KMT2A (0.58) MEN1ALDH1A1KMT2ASMN1; SMN2HPGD
SCHEMBL5714535 0.82 HSD17B10 (0.42) MEN1ALDH1A1KMT2ASMN1; SMN2HPGD
SCHEMBL5715592 0.78 TRPA1 (0.47) MEN1ALDH1A1KMT2ASMN1; SMN2TRPV1
SCHEMBL5714721 0.78 SMN1; SMN2 (0.65) HTTLMNAMEN1ALDH1A1KMT2A
SCHEMBL5715095 0.78 LIPE (0.78) HTTLMNASMN1; SMN2HPGDL3MBTL1
SCHEMBL5714709 0.77 HTT (0.57) HTTLMNAMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC HTT 812/4885LMNA 1523/4885MEN1 3380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.